Here, we focused on miR-877 because of its association with processes relevant to SCCC, such as p16 activation [3,4], restoration of paclitaxel sensitivity [2], and TLR4 inhibition [46,47,48,49], in bladder cancer [44], hepatocellular carcinoma [32], and glioma [43], respectively. This evidence concerns the gene TLR4 and urinary bladder cancer.